



precisely remodeling tissues.
profoundly reshaping lives.

Teaser

Amalus Therapeutics' mission is to revolutionize the treatment landscape for diseases propelled by corrupted fibroblasts. Utilizing our unique, proprietary POKÉ target discovery platform, we combine the forces of forward genetics, mechanobiology, and data science. This synergy drives our discovery of new strategies aimed at safely and selectively normalizing disease-driving fibroblasts.

Our approach holds great promise in addressing the urgent need for effective therapies across various fibrotic conditions. Our first program centres around an orally available first-in-class small molecule tailored to selectively target cancer-associated fibroblasts (CAFs). By normalizing the microenvironment within stroma-rich cancers, this singular asset has the potential to enhance the efficacy of immune checkpoint inhibitors and conventional chemotherapy.

Currently in the pre-seed phase, Amalus Therapeutics is backed by the esteemed Bio-Innovation Institute accelerator (BII) and has garnered recognition as an OBN One-to-Watch nominee. Our dynamic team is composed of enthusiastic entrepreneurs, bright scientists and biotech veterans. We are dedicated to pioneering innovative solutions in our field, and are backed by a world-class scientific advisory board.

STAFF



Bart Roman
CEO & CO-FOUNDER



Chris Stevens
CO-FOUNDER &
EXECUTIVE BOARD
MEMBER



Dominic De Groot
CO-FOUNDER &
EXECUTIVE BOARD
MEMBER



Luc Van Rompaey
R&D ADVISOR
argenx
Galápagos



Paul Decraemer
FINANCIAL & OPERATIONS
ADVISOR
Capricorn | inbiose



Marlies Burgelman
SCIENTIST BIOLOGY



Kaat D'Hondt
RESEARCH ASSOCIATE

SCIENTIFIC ADVISORY BOARD



Udai Banerji
PHASE I TRIALS
ICR The Institute of
Cancer Research



Giulia Biffi
FIBROBLAST BIOLOGY
UNIVERSITY OF
CAMBRIDGE



Karolien De Bosscher
RECEPTOR SIGNALLING
VIB



Rob Williams
DRUG DISCOVERY
CANCER
RESEARCH
UK

€1M PRE-SEED RAISED FROM

BIOINNOVATION INSTITUTE
VLAIO

COLLABORATORS

BEATSON INSTITUTE
DUTCH CANCER INSTITUTE
VIB CENTER FOR MEDICAL BIOTECHNOLOGY & SCREENING CORE
BRIC – UNIVERSITY OF COPENHAGEN
GHENT UNIVERSITY
IMEC

We are actively pursuing a seed round of **€11 million to materialize an actionable plan** that will bring our lead asset to CTA submission in 2027. An optional additional €2 million will enable us to advance the development of our POKÉ target discovery platform.

*Join us on our mission to revolutionize the targeting of disease-propelling fibroblasts,
and to reshape the lives of people affected by cancer and fibrosis.*